Inogen (INGN) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 revenue reached $88.8 million, up 6.1% year-over-year, driven by strong business-to-business sales, while direct-to-consumer and rental segments declined.
Gross margin improved to 48.1% from 40.7% year-over-year, mainly due to lower component costs and favorable reserve adjustments.
GAAP net loss narrowed to $5.6 million from $9.8 million in Q2 2023; adjusted net loss was $1.6 million versus $5.8 million.
Adjusted EBITDA turned positive at $1.3 million, compared to negative $3.2 million a year ago.
Ended Q2 with $121.2 million in cash, cash equivalents, marketable securities, and restricted cash, with no debt.
Financial highlights
Q2 2024 sales revenue: $74.4 million (+8.9% YoY); rental revenue: $14.3 million (-6.2% YoY); total revenue: $88.8 million (+6.1% YoY).
Direct-to-consumer sales fell 15.6% to $22.6 million; rental revenue down 6.2% to $14.3 million.
Domestic B2B revenue rose 16.5% to $21.3 million; international B2B up 31.1% to $30.5 million.
Total gross margin improved to 48.1%, up from 40.7% in Q2 2023, aided by lower component costs and reserve adjustments.
Operating expenses increased 8.7% to $49.8 million, mainly from higher personnel and advertising costs.
Outlook and guidance
Full-year 2024 revenue expected between $325 million and $330 million, reflecting 3%–5% year-over-year growth.
Gross margins anticipated in the low- to mid-40% range for the second half of 2024.
Guidance reflects anticipated advertising headwinds, fewer DTC leads due to the U.S. election, and ongoing cost pressures.
Current liquidity is expected to be sufficient for at least the next twelve months.
Minimal impact from semiconductor chip inflation expected for the remainder of 2024.
Latest events from Inogen
- Diversifying into respiratory care, achieving financial turnaround, and launching innovative products.INGN
Company presentation20 Mar 2026 - Diversified portfolio and innovation pipeline set to drive growth and profitability.INGN
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - 2025 revenue rose 3.9–4% with improved profitability and a $30M buyback; 2026 targets 6% growth.INGN
Q4 202524 Feb 2026 - Q3 revenue up 5.8%, net loss narrows, gross margin rises, and adjusted EBITDA turns positive.INGN
Q3 202415 Jan 2026 - Leadership overhaul and channel optimization set the stage for profitable growth and innovation.INGN
Stifel 2024 Healthcare Conference13 Jan 2026 - Portfolio expansion and operational improvements position for growth in the under-penetrated respiratory market.INGN
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Strategic partnerships, new products, and digital health focus position for future growth.INGN
24th Annual Needham Virtual Healthcare Conference24 Dec 2025 - 2024 revenue up 6.4%, B2B and new products drive growth; 2025 targets further gains.INGN
Q4 202424 Dec 2025 - Virtual annual meeting to vote on directors, auditor, compensation, and equity plan.INGN
Proxy Filing2 Dec 2025